ELVN — Enliven Therapeutics Share News
0.000.00%
Last trade - 00:00Enliven Therapeutics Q1 net loss narrows as R&D spending reduces
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
Enliven gains after Jones raises PT on increased takeover appeal
Enliven Therapeutics Q4 net loss widens on higher expenses
Brief: Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026
Enliven Therapeutics appoints Rick Fair as new CEO, shares down
Brief: Enliven Therapeutics Announces New CEO To Drive Next Phase Of Development
Enliven Therapeutics Q3 net loss narrows
Brief: Enliven Therapeutics Announces Oral And Poster Presentations At The Society Of Hematologic Oncology (Soho) 2025 Annual Meeting
Enliven Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Enliven Therapeutics Announces Proposed Public Offering Of Common Stock
Enliven Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile
Brief: Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million
Enliven Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Enliven Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Enliven Therapeutics Announces Positive Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia